Search results
Showing 526 to 540 of 2105 results for technology appraisal
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)
Evidence-based recommendations on crovalimab (Piasky) for paroxysmal nocturnal haemoglobinuria in people 12 years and over.
Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)
Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
ENDURALIFE powered CRT-D devices for treating heart failure (HTG433)
Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.
This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.
Show all sections
Sections for NG256
- Overview
- Information and support
- Diagnosis
- Managing oncocytomas and Bosniak 2F cysts
- Managing localised and locally advanced renal cell carcinoma
- Managing advanced renal cell carcinoma
- Managing renal cell carcinoma in people with a heritable renal cell carcinoma predisposition syndrome
- Terms used in this guideline
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.
Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis (TA127)
Evidence-based recommendations on natalizumab (Tysabri) for treating rapidly evolving severe relapsing–remitting multiple sclerosis in adults.
Idelalisib for treating refractory follicular lymphoma (TA604)
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.